Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial (Q29141): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Added [en] label: Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial) |
Superraptor (talk | contribs) (Added [en] alias: Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda) |
||
| aliases / en / 0 | aliases / en / 0 | ||
Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda | |||
Latest revision as of 19:04, 6 November 2024
No description defined
- Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
- Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial |
No description defined |
|
Statements
Peer-delivered HIV self-testing (HIVST) and sexually transmitted infection self-sampling (STISS) may promote adherence to oral pre-exposure prophylaxis (PrEP), but no studies have analyzed this approach among transgender women (TGW) in sub-Saharan Africa. (English)
BACKGROUND (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
The Peer study was a cluster randomized trial in Uganda (October 2020-July 2022; NCT04328025). (English)
SETTING (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Ten TGW peer groups, each with 1 TGW peer and 8 TGW, were randomized 1:1 to receive quarterly in-clinic HIV testing with PrEP refills as standard-of-care (SOC) or SOC plus monthly peer delivery of oral-fluid HIVST, STISS, and PrEP refills (intervention). (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Participants were followed for 12 months. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
The primary outcome was PrEP adherence. (English)
METHODS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
We screened 85 TGW and enrolled 82 (41 per arm). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
The median age was 22 years (interquartile range [IQR] 20-24). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Twelve-month retention was 88% (72/82). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
At the 3, 6, 9, and 12-month clinic visits, 10%, 5%, 5%, and 0% of TGW in the intervention arm had TFV-DP levels ≥700 fmol/punch, versus 7%, 15%, 7%, and 2% in the SOC arm, respectively (P = 0.18). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
At all visits, any detectable TFV-DP levels were significantly higher in SOC than the peer delivery group (P < 0.04). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
PrEP adherence was associated with sex work (incidence rate ratio 6.93; 95% CI: 2.33 to 20.60) and >10 years of schooling (incidence rate ratio 2.35; 95% CI: 1.14 to 4.84). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
There was a strong correlation between tenofovir detection in dried blood spots and urine (P < 0.001). (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
No HIV seroconversions occurred. (English)
RESULTS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Peer-delivered HIVST and STISS did not increase low levels of oral PrEP adherence among TGW in Uganda. (English)
CONCLUSIONS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Long-acting PrEP formulations should be considered for this population. (English)
CONCLUSIONS (English)
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. (English)
2024
Andrew (English)
Mujugira (English)
A
Beyonce (English)
Karungi (English)
B
Agnes (English)
Nakyanzi (English)
A
Monica (English)
Bagaya (English)
M
Rogers (English)
Nsubuga (English)
R
Timothy (English)
Sebuliba (English)
T
Olivia (English)
Nampewo (English)
O
Faith (English)
Naddunga (English)
F
Juliet E (English)
Birungi (English)
JE
Oliver (English)
Sapiri (English)
O
Kikulwe R (English)
Nyanzi (English)
KR
Felix (English)
Bambia (English)
F
Timothy (English)
Muwonge (English)
T
Monica (English)
Gandhi (English)
M
Jessica E (English)
Haberer (English)
JE
12 September 2024
9 September 2024
The research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Grant Number R34MH121084 to A.M. A.M. received research funding outside the submitted work from Gilead Sciences, Inc. J.E.H. (English)
None of the remaining authors declared any conflict of interest. (English)
The authors have no funding or conflicts of interest to disclose. (English)